

# Carlo Ferrari

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5010659/publications.pdf>

Version: 2024-02-01

117  
papers

16,921  
citations

20797

60  
h-index

19726

117  
g-index

119  
all docs

119  
docs citations

119  
times ranked

11745  
citing authors

#	ARTICLE	IF	CITATIONS
1	Long-term serological, virological and histological responses to RNA inhibition by ARC-520 in Chinese chronic hepatitis B patients on entecavir treatment. <i>Gut</i> , 2022, 71, 789-797.	6.1	25
2	Targeting Stress Sensor Kinases in Hepatocellular Carcinoma-Infiltrating Human NK Cells as a Novel Immunotherapeutic Strategy for Liver Cancer. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	2
3	Metabolic regulation of the HBV-specific T cell function. <i>Antiviral Research</i> , 2021, 185, 104989.	1.9	9
4	Functional reconstitution of HBV-specific CD8 T cells by in vitro polyphenol treatment in chronic hepatitis B. <i>Journal of Hepatology</i> , 2021, 74, 783-793.	1.8	33
5	Intratumor Regulatory Noncytotoxic NK Cells in Patients with Hepatocellular Carcinoma. <i>Cells</i> , 2021, 10, 614.	1.8	24
6	A Simplified SARS-CoV-2 Pseudovirus Neutralization Assay. <i>Vaccines</i> , 2021, 9, 389.	2.1	30
7	X Chromosome Contribution to the Genetic Architecture of Primary Biliary Cholangitis. <i>Gastroenterology</i> , 2021, 160, 2483-2495.e26.	0.6	27
8	An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs. <i>Journal of Hepatology</i> , 2021, 75, 572-581.	1.8	62
9	Guidance for Design and Endpoints of Clinical Trials in Chronic Hepatitis B Report From the 2019 EASL AASLD HBV Treatment Endpoints Conference. <i>Hepatology</i> , 2020, 71, 1070-1092.	3.6	52
10	RNA Interference Therapy With ARC-520 Results in Prolonged Hepatitis B Surface Antigen Response in Patients With Chronic Hepatitis B Infection. <i>Hepatology</i> , 2020, 72, 19-31.	3.6	84
11	Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL AASLD HBV Treatment Endpoints Conference. <i>Journal of Hepatology</i> , 2020, 72, 539-557.	1.8	208
12	DNA Methylation and Immune Cell Markers Demonstrate Evidence of Accelerated Aging in Patients with Chronic Hepatitis B Virus or Hepatitis C Virus, with or without Human Immunodeficient Virus Co-infection. <i>Clinical Infectious Diseases</i> , 2020, 73, e184-e190.	2.9	13
13	Pathogenetic Mechanisms of T Cell Dysfunction in Chronic HBV Infection and Related Therapeutic Approaches. <i>Frontiers in Immunology</i> , 2020, 11, 849.	2.2	79
14	Energy metabolism and cell motility defect in NK-cells from patients with hepatocellular carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 1589-1603.	2.0	16
15	Targeting p53 and histone methyltransferases restores exhausted CD8+ T cells in HCV infection. <i>Nature Communications</i> , 2020, 11, 604.	5.8	44
16	The Good and the Bad of Natural Killer Cells in Virus Control: Perspective for Anti-HBV Therapy. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5080.	1.8	39
17	HBV Immune-Therapy: From Molecular Mechanisms to Clinical Applications. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2754.	1.8	43
18	Combined GS-4774 and Tenofovir Therapy Can Improve HBV-Specific T-Cell Responses in Patients With Chronic Hepatitis. <i>Gastroenterology</i> , 2019, 157, 227-241.e7.	0.6	99

#	ARTICLE	IF	CITATIONS
19	Update of the statements on biology and clinical impact of occult hepatitis B virus infection. <i>Journal of Hepatology</i> , 2019, 71, 397-408.	1.8	341
20	A global scientific strategy to cure hepatitis B. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 545-558.	3.7	342
21	Aggressive Surgical Approach for Treatment of Primary and Recurrent Retroperitoneal Soft Tissue Sarcoma. <i>Indian Journal of Surgery</i> , 2018, 80, 154-162.	0.2	7
22	TLR7 Agonist Increases Responses of Hepatitis B Virus-Specific T Cells and Natural Killer Cells in Patients With Chronic Hepatitis B Treated With Nucleos(T)ide Analogues. <i>Gastroenterology</i> , 2018, 154, 1764-1777.e7.	0.6	123
23	Strategies to overcome HBV-specific T cell exhaustion: checkpoint inhibitors and metabolic re-programming. <i>Current Opinion in Virology</i> , 2018, 30, 1-8.	2.6	36
24	Safety, efficacy and pharmacodynamics of vesatolimod (GS-9620) in virally suppressed patients with chronic hepatitis B. <i>Journal of Hepatology</i> , 2018, 68, 431-440.	1.8	147
25	Liver Resection or Resection plus Intraoperative Echo-Guided Ablation in the Treatment of Colorectal Metastases: We are Evaluating Their Effect for Cure. <i>American Surgeon</i> , 2018, 84, 1509-1517.	0.4	0
26	Targeting mitochondrial dysfunction can restore antiviral activity of exhausted HBV-specific CD8 T cells in chronic hepatitis B. <i>Nature Medicine</i> , 2017, 23, 327-336.	15.2	251
27	T cell regulation in HBV-related chronic liver disease. <i>Journal of Hepatology</i> , 2017, 66, 1096-1098.	1.8	14
28	Treatment of Hepatitis C virus infection in Italy: A consensus report from an expert panel. <i>Digestive and Liver Disease</i> , 2017, 49, 731-741.	0.4	19
29	Effector CD8+ T cell-derived interleukin-10 enhances acute liver immunopathology. <i>Journal of Hepatology</i> , 2017, 67, 543-548.	1.8	48
30	RNAi-based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis B virus DNA is a source of HBsAg. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	343
31	Gene expression analysis during acute hepatitis C virus infection associates dendritic cell activation with viral clearance. <i>Journal of Medical Virology</i> , 2016, 88, 843-851.	2.5	3
32	Randomized phase II study of GS-4774 as a therapeutic vaccine in virally suppressed patients with chronic hepatitis B. <i>Journal of Hepatology</i> , 2016, 65, 509-516.	1.8	142
33	Adaptive immunity in HBV infection. <i>Journal of Hepatology</i> , 2016, 64, S71-S83.	1.8	358
34	Resection of the Primary Tumor Followed by Peptide Receptor Radionuclide Therapy as Upfront Strategy for the Treatment of G1-G2 Pancreatic Neuroendocrine Tumors with Unresectable Liver Metastases. <i>Annals of Surgical Oncology</i> , 2016, 23, 981-989.	0.7	58
35	Missed treatment in an Italian HBV infected patients cohort: HBV RER. <i>Digestive and Liver Disease</i> , 2016, 48, 1346-1350.	0.4	2
36	Mutual relationship between serum ferroxidase activity and hemoglobin levels in elderly individuals. <i>Annals of Hematology</i> , 2016, 95, 1333-1339.	0.8	1

#	ARTICLE	IF	CITATIONS
37	From current status to optimization of HCV treatment: Recommendations from an expert panel. <i>Digestive and Liver Disease</i> , 2016, 48, 995-1005.	0.4	13
38	Optimizing treatment of hepatic metastases from colorectal cancer: Resection or resection plus ablation?. <i>International Journal of Oncology</i> , 2016, 48, 1280-1289.	1.4	10
39	Natural killer cells phenotypic characterization as an outcome predictor of HCV-linked HCC after curative treatments. <i>Oncolimmunology</i> , 2016, 5, e1154249.	2.1	37
40	Changes in Protein Expression in Two Cholangiocarcinoma Cell Lines Undergoing Formation of Multicellular Tumor Spheroids In Vitro. <i>PLoS ONE</i> , 2015, 10, e0118906.	1.1	16
41	<sc>HBV</sc> and the immune response. <i>Liver International</i> , 2015, 35, 121-128.	1.9	153
42	Natural killer cell phenotype modulation and natural killer/Tâ€œcell interplay in nucleos(t)ide analogueâ€œtreated hepatitis e antigenâ€œnegative patients with chronic hepatitis B. <i>Hepatology</i> , 2015, 62, 1697-1709.	3.6	73
43	HLA and Killer Immunoglobulin-like Receptor Genes as Outcome Predictors of Hepatitis C Virusâ€œRelated Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2013, 19, 5465-5473.	3.2	46
44	Republished: Innate and adaptive immune responses in chronic hepatitis B virus infections: towards restoration of immune control of viral infection. <i>Postgraduate Medical Journal</i> , 2013, 89, 294-304.	0.9	49
45	Impact of Soluble CD26 on Treatment Outcome and Hepatitis C Virus-Specific T Cells in Chronic Hepatitis C Virus Genotype 1 Infection. <i>PLoS ONE</i> , 2013, 8, e56991.	1.1	12
46	Mobilizing monocytes to cross-present circulating viral antigen in chronic infection. <i>Journal of Clinical Investigation</i> , 2013, 123, 3766-3776.	3.9	80
47	Lack of full CD8 functional restoration after antiviral treatment for acute and chronic hepatitis C virus infection. <i>Gut</i> , 2012, 61, 1076-1084.	6.1	51
48	Innate and adaptive immune responses in chronic hepatitis B virus infections: towards restoration of immune control of viral infection. <i>Gut</i> , 2012, 61, 1754-1764.	6.1	387
49	Peginterferon-Î± does not improve early peripheral blood HBV-specific T-cell responses in HBeAg-negative chronic hepatitis. <i>Journal of Hepatology</i> , 2012, 56, 1239-1246.	1.8	75
50	Increased Levels of Arginase in Patients With Acute Hepatitis B Suppress Antiviral T Cells. <i>Gastroenterology</i> , 2012, 143, 78-87.e3.	0.6	63
51	Restored Function of HBV-Specific T Cells After Long-term Effective Therapy With Nucleos(t)ide Analogues. <i>Gastroenterology</i> , 2012, 143, 963-973.e9.	0.6	308
52	Combined Blockade of Programmed Death-1 and Activation of CD137 Increase Responses of Human Liver T Cells Against HBV, But Not HCV. <i>Gastroenterology</i> , 2012, 143, 1576-1585.e4.	0.6	106
53	Immunological and Molecular Correlates of Disease Recurrence after Liver Resection for Hepatocellular Carcinoma. <i>PLoS ONE</i> , 2012, 7, e32493.	1.1	61
54	Effects of the regulatory ligands calcium and GTP on the thermal stability of tissue transglutaminase. <i>Amino Acids</i> , 2012, 42, 2233-2242.	1.2	3

#	ARTICLE	IF	CITATIONS
55	Long-term effects of treatment and response in patients with chronic hepatitis C on quality of life. An international, multicenter, randomized, controlled study. <i>BMC Gastroenterology</i> , 2012, 12, 11.	0.8	30
56	Treatment of chronic hepatitis B: Update of the recommendations from the 2007 Italian Workshop. <i>Digestive and Liver Disease</i> , 2011, 43, 259-265.	0.4	29
57	Response Prediction in Chronic Hepatitis C by Assessment of IP-10 and IL28B-Related Single Nucleotide Polymorphisms. <i>PLoS ONE</i> , 2011, 6, e17232.	1.1	131
58	The Host-Pathogen Interaction during HBV Infection: Immunological Controversies. <i>Antiviral Therapy</i> , 2010, 15, 15-24.	0.6	96
59	Systemic and intrahepatic interferon-gamma-inducible protein 10 kDa predicts the first-phase decline in hepatitis C virus RNA and overall viral response to therapy in chronic hepatitis C. <i>Hepatology</i> , 2010, 51, 1523-1530.	3.6	105
60	Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis. <i>Nature Genetics</i> , 2010, 42, 658-660.	9.4	389
61	Contribution of Herpesvirus Specific CD8 T Cells to Anti-Viral T Cell Response in Humans. <i>PLoS Pathogens</i> , 2010, 6, e1001051.	2.1	72
62	Antiviral Intrahepatic T-Cell Responses Can Be Restored by Blocking Programmed Death-1 Pathway in Chronic Hepatitis B. <i>Gastroenterology</i> , 2010, 138, 682-693.e4.	0.6	416
63	Radiofrequency Thermal Ablation for Hepatocellular Carcinoma Stimulates Autologous NK-Cell Response. <i>Gastroenterology</i> , 2010, 138, 1931-1942.e2.	0.6	154
64	Activation of Natural Killer Cells During Acute Infection With Hepatitis C Virus. <i>Gastroenterology</i> , 2010, 138, 1536-1545.	0.6	162
65	The Characteristics of the Cell-Mediated Immune Response Identify Different Profiles of Occult Hepatitis B Virus Infection. <i>Gastroenterology</i> , 2008, 134, 1470-1481.	0.6	115
66	Therapeutic Vaccination for Hepatitis C: Can Protective T-Cell Responses Be Restored After Prolonged Antigen Exposure?. <i>Gastroenterology</i> , 2008, 134, 1601-1604.	0.6	7
67	Restoration of HCV-specific T cell functions by PD-1/PD-L1 blockade in HCV infection: Effect of viremia levels and antiviral treatment. <i>Journal of Hepatology</i> , 2008, 48, 548-558.	1.8	113
68	Hepatitis C viral kinetics in plasma and peripheral blood mononuclear cells during pegylated interferon- $\alpha$ 2a/ribavirin therapy. <i>Journal of Hepatology</i> , 2008, 48, 932-938.	1.8	7
69	A non-invasive fibrosis score predicts treatment outcome in chronic hepatitis C virus infection. <i>Scandinavian Journal of Gastroenterology</i> , 2008, 43, 73-80.	0.6	29
70	Host Ethnicity and Virus Genotype Shape the Hepatitis B Virus-Specific T-Cell Repertoire. <i>Journal of Virology</i> , 2008, 82, 10986-10997.	1.5	114
71	Increased Immunostimulatory Activity Conferred to Antigen-presenting Cells by Exposure to Antigen Extract From Hepatocellular Carcinoma After Radiofrequency Thermal Ablation. <i>Journal of Immunotherapy</i> , 2008, 31, 271-282.	1.2	72
72	Characterization of Hepatitis B Virus (HBV)-Specific T-Cell Dysfunction in Chronic HBV Infection. <i>Journal of Virology</i> , 2007, 81, 4215-4225.	1.5	801

#	ARTICLE	IF	CITATIONS
73	Therapeutic vaccination of chronic hepatitis B patients with virus suppression by antiviral therapy: A randomized, controlled study of co-administration of HBsAg/AS02 candidate vaccine and lamivudine. <i>Vaccine</i> , 2007, 25, 8585-8597.	1.7	160
74	T and B Cells in Hepatitis C Virus Control: What They Do and When They Fail. <i>Gastroenterology</i> , 2007, 132, 801-805.	0.6	6
75	HCV-Specific T-Cell Response in Relation to Viral Kinetics and Treatment Outcome (DITTO-HCV Project). <i>Gastroenterology</i> , 2007, 133, 1132-1143.	0.6	57
76	Predicting treatment outcome following 24 weeks peginterferon $\alpha$ -2a/ribavirin therapy in patients infected with HCV genotype 1: Utility of HCV-RNA at day 0, day 22, day 29, and week 6. <i>Hepatology</i> , 2007, 45, 258-259.	3.6	6
77	Dysfunction and functional restoration of HCV-specific CD8 responses in chronic hepatitis C virus infection. <i>Hepatology</i> , 2007, 45, 588-601.	3.6	266
78	Impact of disease severity on outcome of antiviral therapy in treatment-naïve patients with chronic hepatitis C. <i>Hepatology</i> , 2007, 45, 1333-1334.	3.6	3
79	New perspectives for T-cell-based HCV vaccines. <i>Journal of Hepatology</i> , 2006, 45, 163-165.	1.8	6
80	The influence of T cell cross-reactivity on HCV-peptide specific human T cell response. <i>Hepatology</i> , 2006, 43, 602-611.	3.6	35
81	Outcome of acute hepatitis C is related to virus-specific CD4 function and maturation of antiviral memory CD8 responses. <i>Hepatology</i> , 2006, 44, 126-139.	3.6	176
82	IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection. <i>Hepatology</i> , 2006, 44, 1617-1625.	3.6	193
83	Interferon (IFN) $\alpha$ 2a-Inducible Protein $\alpha$ 10: Association with Histological Results, Viral Kinetics, and Outcome during Treatment with Pegylated IFN $\alpha$ 2a and Ribavirin for Chronic Hepatitis C Virus Infection. <i>Journal of Infectious Diseases</i> , 2006, 194, 895-903.	1.9	201
84	Radiofrequency Thermal Ablation of Hepatocellular Carcinoma Liver Nodules Can Activate and Enhance Tumor-Specific T-Cell Responses. <i>Cancer Research</i> , 2006, 66, 1139-1146.	0.4	236
85	PD-1 Expression in Acute Hepatitis C Virus (HCV) Infection Is Associated with HCV-Specific CD8 Exhaustion. <i>Journal of Virology</i> , 2006, 80, 11398-11403.	1.5	521
86	Acute phase HBV-specific T cell responses associated with HBV persistence after HBV/HCV coinfection. <i>Hepatology</i> , 2005, 41, 826-831.	3.6	57
87	T Cells with a CD4 + CD25 + Regulatory Phenotype Suppress In Vitro Proliferation of Virus-Specific CD8 + T Cells during Chronic Hepatitis C Virus Infection. <i>Journal of Virology</i> , 2005, 79, 7860-7867.	1.5	386
88	The Impairment of CD8 Responses Limits the Selection of Escape Mutations in Acute Hepatitis C Virus Infection. <i>Journal of Immunology</i> , 2005, 175, 7519-7529.	0.4	57
89	Heterologous T cell immunity in severe hepatitis C virus infection. <i>Journal of Experimental Medicine</i> , 2005, 201, 675-680.	4.2	134
90	International, multicenter, randomized, controlled study comparing dynamically individualized versus standard treatment in patients with chronic hepatitis C. <i>Journal of Hepatology</i> , 2005, 43, 250-257.	1.8	143

#	ARTICLE	IF	CITATIONS
91	Antiviral CD8-mediated responses in chronic HCV carriers with HBV superinfection. <i>Hepatology</i> , 2004, 40, 289-299.	3.6	13
92	Ex vivo characterization of tumor-derived melanoma antigen encoding gene-specific CD8+ cells in patients with hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2004, 40, 102-109.	1.8	66
93	Kinetics of the immune response during HBV and HCV infection. <i>Hepatology</i> , 2003, 38, 4-13.	3.6	227
94	Immunopathogenesis of hepatitis B. <i>Journal of Hepatology</i> , 2003, 39, 36-42.	1.8	67
95	Transient restoration of anti-viral T cell responses induced by lamivudine therapy in chronic hepatitis B. <i>Journal of Hepatology</i> , 2003, 39, 595-605.	1.8	229
96	Virus-Specific CD8+ Lymphocytes Share the Same Effector-Memory Phenotype but Exhibit Functional Differences in Acute Hepatitis B and C. <i>Journal of Virology</i> , 2002, 76, 12423-12434.	1.5	168
97	Viral determinants and host immune responses in the pathogenesis of HBV infection. <i>Journal of Medical Virology</i> , 2002, 67, 454-457.	2.5	55
98	Oral lichen planus pathogenesis: A role for the HCV-specific cellular immune response. <i>Hepatology</i> , 2002, 36, 1446-1452.	3.6	53
99	Intrahepatic and circulating HLA class II-restricted, hepatitis C virus-specific T cells: Functional characterization in patients with chronic hepatitis C. <i>Hepatology</i> , 2002, 35, 1225-1236.	3.6	68
100	Comparative pathogenesis of HBV and HCV. <i>Virus Research</i> , 2001, 82, 19-23.	1.1	5
101	Identification of immunodominant hepatitis C virus (HCV)-specific cytotoxic T-cell epitopes by stimulation with endogenously synthesized HCV antigens. <i>Hepatology</i> , 2001, 33, 1533-1543.	3.6	40
102	CD8+ T lymphocyte responses are induced during acute hepatitis C virus infection but are not sustained. <i>European Journal of Immunology</i> , 2000, 30, 2479-2487.	1.6	297
103	The Role of Virus-Specific Cd8+ Cells in Liver Damage and Viral Control during Persistent Hepatitis B Virus Infection. <i>Journal of Experimental Medicine</i> , 2000, 191, 1269-1280.	4.2	761
104	Conserved hepatitis C virus sequences are highly immunogenic for CD4+ T cells: Implications for vaccine development. <i>Hepatology</i> , 1999, 30, 1088-1098.	3.6	150
105	Immunopathogenesis of hepatitis C virus infection. <i>Journal of Hepatology</i> , 1999, 31, 31-38.	1.8	26
106	Direct ex vivo analysis of hepatitis B virus-specific CD8+ T cells associated with the control of infection. <i>Gastroenterology</i> , 1999, 117, 1386-1396.	0.6	331
107	Is antigenic variability a strategy adopted by hepatitis B virus to escape cytotoxic T-lymphocyte surveillance?. <i>Seminars in Virology</i> , 1996, 7, 23-30.	4.1	8
108	The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T lymphocyte response. <i>Nature Medicine</i> , 1996, 2, 1104-1108.	15.2	804

#	ARTICLE	IF	CITATIONS
109	Hepatitis B virus immunopathology. <i>Seminars in Immunopathology</i> , 1995, 17, 261-81.	4.0	120
110	Hepatitis B Virus Immunopathogenesis. <i>Annual Review of Immunology</i> , 1995, 13, 29-60.	9.5	1,550
111	T-cell response to structural and nonstructural hepatitis C virus antigens in persistent and self-limited hepatitis C virus infections. <i>Hepatology</i> , 1994, 19, 286-295.	3.6	238
112	Natural variants of cytotoxic epitopes are T-cell receptor antagonists for antiviral cytotoxic T cells. <i>Nature</i> , 1994, 369, 407-410.	13.7	572
113	Hepatitis C virus viremia following clinical resolution of acute hepatitis C. <i>Journal of Hepatology</i> , 1994, 20, 666-671.	1.8	49
114	Fine specificity of the human T-cell response to the hepatitis B virus preS1 antigen. <i>Gastroenterology</i> , 1992, 103, 255-263.	0.6	50
115	Long-term follow-up of anti-hepatitis C virus antibodies in patients with acute nonA nonB hepatitis and different outcome of liver disease. <i>Liver</i> , 1992, 12, 94-99.	0.1	17
116	Hepatitis B virus structure and biology. <i>Microbial Pathogenesis</i> , 1989, 6, 311-325.	1.3	78
117	Evaluation of monoclonality of cell lines from sequential dilution assays. <i>Journal of Immunological Methods</i> , 1987, 105, 139-143.	0.6	13